11/12
08:03 am
argx
argenx SE (NASDAQ: ARGX) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating. They now have a $697.00 price target on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating. They now have a $697.00 price target on the stock.
11/11
07:30 am
argx
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
Low
Report
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
11/5
07:27 am
argx
argenx SE (NASDAQ: ARGX) was upgraded by analysts at Scotiabank from a "sector perform" rating to a "sector outperform" rating. They now have a $715.00 price target on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) was upgraded by analysts at Scotiabank from a "sector perform" rating to a "sector outperform" rating. They now have a $715.00 price target on the stock.
11/5
07:27 am
argx
argenx SE (NASDAQ: ARGX) was upgraded by analysts at Scotiabank from a "sector perform" rating to a "sector outperform" rating. They now have a $715.00 price target on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) was upgraded by analysts at Scotiabank from a "sector perform" rating to a "sector outperform" rating. They now have a $715.00 price target on the stock.
11/5
01:00 am
argx
argenx to Participate at Upcoming Investor Conferences
Low
Report
argenx to Participate at Upcoming Investor Conferences
11/4
09:31 am
argx
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at JPMorgan Chase & Co. from $640.00 to $670.00. They now have an "overweight" rating on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at JPMorgan Chase & Co. from $640.00 to $670.00. They now have an "overweight" rating on the stock.
11/2
06:52 am
argx
argenx SE (NASDAQ: ARGX) was downgraded by analysts at Baird R W from a "strong-buy" rating to a "hold" rating.
Low
Report
argenx SE (NASDAQ: ARGX) was downgraded by analysts at Baird R W from a "strong-buy" rating to a "hold" rating.
11/1
03:39 pm
argx
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Guggenheim from $585.00 to $665.00. They now have a "buy" rating on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Guggenheim from $585.00 to $665.00. They now have a "buy" rating on the stock.
11/1
02:51 pm
argx
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Wells Fargo & Company from $547.00 to $639.00. They now have an "overweight" rating on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Wells Fargo & Company from $547.00 to $639.00. They now have an "overweight" rating on the stock.
11/1
10:34 am
argx
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Piper Sandler from $553.00 to $620.00. They now have an "overweight" rating on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Piper Sandler from $553.00 to $620.00. They now have an "overweight" rating on the stock.
11/1
09:40 am
argx
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $560.00 to $646.00. They now have an "outperform" rating on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $560.00 to $646.00. They now have an "outperform" rating on the stock.
11/1
08:32 am
argx
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at JMP Securities from $497.00 to $606.00. They now have a "market outperform" rating on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at JMP Securities from $497.00 to $606.00. They now have a "market outperform" rating on the stock.
11/1
08:15 am
argx
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at HC Wainwright from $533.00 to $617.00. They now have a "buy" rating on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at HC Wainwright from $533.00 to $617.00. They now have a "buy" rating on the stock.
11/1
07:32 am
argx
argenx SE (NASDAQ: ARGX) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. They now have a $650.00 price target on the stock, up previously from $515.00.
Low
Report
argenx SE (NASDAQ: ARGX) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. They now have a $650.00 price target on the stock, up previously from $515.00.
11/1
07:32 am
argx
argenx SE (NASDAQ: ARGX) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.
Low
Report
argenx SE (NASDAQ: ARGX) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.
10/31
02:35 pm
argx
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Truist Financial Co. from $540.00 to $660.00. They now have a "buy" rating on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Truist Financial Co. from $540.00 to $660.00. They now have a "buy" rating on the stock.
10/31
02:00 am
argx
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
10/24
01:00 am
argx
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
Low
Report
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
10/17
03:49 pm
argx
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Citigroup Inc. from $512.00 to $635.00. They now have a "buy" rating on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Citigroup Inc. from $512.00 to $635.00. They now have a "buy" rating on the stock.
10/15
01:00 am
argx
argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
Low
Report
argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
10/10
09:36 am
argx
argenx SE (NASDAQ: ARGX) had its "strong-buy" rating re-affirmed by analysts at Raymond James. They now have a $605.00 price target on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) had its "strong-buy" rating re-affirmed by analysts at Raymond James. They now have a $605.00 price target on the stock.
10/4
07:36 am
argx
argenx SE (NASDAQ: ARGX) was downgraded by analysts at Deutsche Bank Aktiengesellschaft from a "buy" rating to a "hold" rating.
Low
Report
argenx SE (NASDAQ: ARGX) was downgraded by analysts at Deutsche Bank Aktiengesellschaft from a "buy" rating to a "hold" rating.
9/26
12:16 pm
argx
argenx SE (NASDAQ: ARGX) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $585.00 price target on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $585.00 price target on the stock.
9/19
01:00 am
argx
argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
Low
Report
argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
9/12
10:19 pm
argx
Here's Why argenx SE (ARGX) Rose 9% in Q2 [Yahoo! Finance]
Low
Report
Here's Why argenx SE (ARGX) Rose 9% in Q2 [Yahoo! Finance]